Crossject (PA:ALCJ) — Market Cap & Net Worth
Market Cap & Net Worth: Crossject (ALCJ)
Crossject (PA:ALCJ) has a market capitalization of $110.24 Million (€94.30 Million) as of May 4, 2026. Listed on the PA stock exchange, this France-based company holds position #18801 globally and #283 in its home market, demonstrating a -4.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crossject's stock price €1.90 by its total outstanding shares 52495622 (52.50 Million). Analyse how efficiently does Crossject generate cash to see how efficiently the company converts income to cash.
Crossject Market Cap History: 2015 to 2026
Crossject's market capitalization history from 2015 to 2026. Data shows change from $600.77 Million to $116.85 Million (-6.48% CAGR).
Index Memberships
Crossject is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$35.32 Billion | 0.31% | #20 of 34 |
Weight: Crossject's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Crossject Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crossject's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.11x
Crossject's market cap is 33.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $600.77 Million | $1.59 Million | -$5.69 Million | 378.79x | N/A |
| 2016 | $262.58 Million | $1.42 Million | -$6.66 Million | 184.57x | N/A |
| 2017 | $271.21 Million | $3.23 Million | -$7.61 Million | 83.85x | N/A |
| 2018 | $72.95 Million | $2.44 Million | -$10.71 Million | 29.85x | N/A |
| 2019 | $139.13 Million | $500.00K | -$7.17 Million | 278.25x | N/A |
| 2020 | $185.40 Million | $4.84 Million | -$9.84 Million | 38.27x | N/A |
| 2021 | $172.40 Million | $912.00K | -$10.81 Million | 189.03x | N/A |
| 2022 | $200.46 Million | $954.00K | -$11.16 Million | 210.13x | N/A |
| 2023 | $302.36 Million | $145.00K | -$8.64 Million | 2085.24x | N/A |
| 2024 | $136.25 Million | $4.12 Million | -$12.79 Million | 33.11x | N/A |
Competitor Companies of ALCJ by Market Capitalization
Companies near Crossject in the global market cap rankings as of May 4, 2026.
Key companies related to Crossject by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #136 globally with a market cap of $162.57 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #250 globally with a market cap of $98.12 Billion USD ( €83.93 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #274 globally with a market cap of $93.24 Billion USD ( €79.76 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #523 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #136 | Intuitive Surgical Inc | NASDAQ:ISRG | $162.57 Billion | $457.78 |
| #250 | EssilorLuxottica S. A. | PA:EL | $98.12 Billion | €181.25 |
| #274 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $93.24 Billion | €88.50 |
| #523 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Crossject Historical Marketcap From 2015 to 2026
Between 2015 and today, Crossject's market cap moved from $600.77 Million to $ 116.85 Million, with a yearly change of -6.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €116.85 Million | -13.06% |
| 2025 | €134.41 Million | -1.35% |
| 2024 | €136.25 Million | -54.94% |
| 2023 | €302.36 Million | +50.83% |
| 2022 | €200.46 Million | +16.28% |
| 2021 | €172.40 Million | -7.01% |
| 2020 | €185.40 Million | +33.26% |
| 2019 | €139.13 Million | +90.72% |
| 2018 | €72.95 Million | -73.10% |
| 2017 | €271.21 Million | +3.28% |
| 2016 | €262.58 Million | -56.29% |
| 2015 | €600.77 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Crossject was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $110.24 Million USD |
| MoneyControl | $110.24 Million USD |
| MarketWatch | $110.24 Million USD |
| marketcap.company | $110.24 Million USD |
| Reuters | $110.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more